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ABSTRACT 
The Effect of CD2118 on Clostridium difficile Bile Acid Resistance. (May 2013) 
Sarah Louise Schmidt 
Department of Biology 
Texas A&M University 
Research Advisor: Dr. Joseph Sorg 
Department of Biology 
 
 
 
Clostridium difficile is a Gram-positive, anaerobic, spore-forming bacteria that is the leading 
cause of antibiotic-associated diarrhea.  C. difficile infections (CDI) are thought to be caused by 
ingestion of spores by a host with an altered intestinal flora, often caused by antibiotic treatments 
for unrelated conditions. C. difficile spores germinate in vivo when exposed to bile acids, which 
are commonly toxic to bacterial pathogens, and glycine. The proliferation of the resulting 
vegetative cells suggests the presence of mechanism(s) to resist bile acid-mediated toxicity. 
Previous studies identified genes with altered mRNA abundance following bile acid exposure. 
The expression of C. difficile CD2118 increased 20-fold upon exposure to cholic acid or 
deoxycholic acid.  C. difficile CD2118 encodes a putative ABC (ATP-binding cassette) 
transporter, a class of transporters known to participate in bile acid resistance mechanisms of 
other Gram-positive bacteria.  Herein, we characterize the role of CD2118 in protecting C. 
difficile against bile acid-mediated toxicity by constructing a site-directed mutation in the coding 
region of C. difficile CD2118 using the TargeTron system.   
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CHAPTER I 
INTRODUCTION 
 
Clostridium difficile is a Gram-positive, spore-forming, bacteria. C. difficile is a strict anaerobe 
when in the vegetative state, but spores are able to tolerate oxygen and dry conditions (1). 
Exposure to C. difficile in hospital settings can occur when the spores are spread from infected 
patients to susceptible individuals by spore carriage on the gloves and clothing of healthcare 
providers, contaminated surfaces, and aerosols. Community-acquired CDI (CA-CDI) has also 
been reported, usually affecting the very young and those with chronic gastrointestinal 
conditions. Broad-spectrum antibiotic use is normally not associated with these cases, but a few 
have been reported following fluoroquinolone use (2). CA-CDI is much less common than 
hospital-acquired CDI, however, it is becoming more prevalent. Hospital-acquired CDI is usually 
precipitated by use of broad-spectrum antibiotics, which disrupt the balance of the natural 
intestinal microbiota of the host (1). C. difficile spores ingested by the host germinate and then 
proliferate, possibly due to increased nutrient availability and decreased levels of antimicrobial 
compounds normally produced by the natural flora. Vegetative C. difficile also demonstrates 
resistance against host-synthesized antimicrobial compounds such as bile acids and CAMPs 
(cationic antimicrobial peptides) (3). The symptoms normally associated with CDI are caused by 
two toxins, TcdA and TcdB, which disrupt the actin cytoskeleton of colonic epithelial cells (2). 
These toxins enter colonic epithelial cells through receptor-mediated endocytosis and the 
catalytic domain then enters into the host cell cytosol through a pore formed in the endosome and 
catalyzes the UDP-dependent glucosylation of Rho family of GTPases (4). The subsequent 
inhibition of the host Rho GTPases results in a catastrophic signaling cascade that leads to 
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morphological changes in the cell and apoptosis (5). TcdA and TcdB are produced only upon 
germination of the spore into a vegetative cell. Germination of C. difficile spores in the host is 
location-specific. Glycine and bile acids serve as signaling molecules and trigger the transition 
from spore to vegetative state (6). 
 
Bile acids are biosynthesized in the liver from cholesterol and aid in absorption of fat and 
cholesterol during digestion (7). Because C. difficile spores use bile acids as signals to germinate, 
vegetative cells must be able to survive and multiply in their presence, an unusual ability given 
the toxicity of bile acids to many other bacterial pathogens (6). Bile acids cause lysis by 
increasing permeability of the cell membrane. If bile acids enter the cell without causing 
immediate lysis, cytoplasmic bile acids can lead to secondary structure formation in RNA, DNA 
damage, misfolding or denaturation of proteins, or damage from generation of free oxygen 
radicals. Cytoplasmic bile acids will also acidify the cytosol upon dissociation and cause further 
cellular stress and damage (8). Bacteria that colonize the small intestine have a variety of 
mechanisms to circumvent the antimicrobial actions of bile acids. One example is Listeria 
monocytogenes, the causative agent of listeriosis (a form of food poisoning). Like C. difficile, it 
is Gram-positive, but it is able to survive in a much wider range of environmental conditions. In 
order to resist the effects of bile acids, L. monocytogenes utilizes a bile salt hydrolase, a 
membrane-located bile exclusion system, and the regulatory factor sigma B, which increases 
expression of certain genes in response to environmental stressors like bile acids. The specifics 
of the C. difficile bile acid resistance mechanisms are unknown. 
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In preliminary studies, log-phase C. difficile was exposed to sub-MIC (minimal inhibitory 
concentration) levels of cholic acid and deoxycholic acid (bile acids).  Total RNA was isolated 
and analyzed by RNAseq.  This led to the identification of genes with altered mRNA abundance 
upon bile acid exposure. C. difficile CD2118 showed twenty-fold increase in mRNA abundance 
upon bile acid exposure, suggesting it may contribute to bile acid resistance (Allen and Sorg, 
unpublished). The gene CD2118 codes for an ABC (ATP-binding cassette) transporter, a 
transporter class that participates in several cellular processes, including CAMP and clindamycin 
resistance in C. difficile (3, 9). The role of CD2118 in bile acid resistance will be evaluated by 
rendering it nonfunctional through mutation and comparing the bile acid MIC (minimal 
inhibitory concentration) of mutants to that of wild-type C. difficile. The mutation of CD2118 
will be introduced using the TargeTron system, which is currently the most reliable method for 
Clostridium mutagenesis. This system utilizes retargeted Group II introns, which insert directly 
into the gene of interest, and a retro-transposition-activated marker (RAM), which activates a 
lincomycin resistance gene upon successful insertion at the target site. Target sites are 
determined using a computer algorithm, which predicts the probability of successful insertion 
into specific areas of the gene. This method requires assembly of DNA fragments through PCR, 
usage of various recombinant vectors in Escherichia coli, and conjugation between Bacillus 
subtilis and C. difficile. Antibiotic screening is used throughout to eliminate contaminants and to 
verify the success of each step in the process (10).  If complementation to CD2118 via plasmid 
genes restores mutants to wild type MIC for bile acids, it can be assumed that CD2118 plays a 
role in the C. difficile bile acid resistance mechanism. 
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CHAPTER II 
METHODS 
Strains and growth conditions 
Table 1 lists the plasmids and bacterial strains used in this project. All strains were grown at 
37⁰C. Escherichia coli DH5α and MB3436 were grown in Luria Broth (LB) medium 
supplemented with 50 μg/mL kanamycin or 20 μg/mL chloramphenicol as needed (11). Bacillus 
subtilis Bs49 was grown in Brain Heart Infusion supplemented with 5 g/L yeast extract and 0.1% 
L-cysteine (BHIS) or LB medium, supplemented with 2.5 μg/mL chloramphenicol and/or 5 
μg/mL tetracycline (12). Clostridium difficile UK1 was grown in an anaerobic environment (10% 
hydrogen, 5% carbon dioxide, 85% nitrogen) in BHIS medium and antibiotics (10 μg/mL 
thiamphenicol, 50 μg/mL kanamycin, 5 μg/mL tetracycline, and 20 μg/mL lincomycin) were 
added where indicated (13). 
 
Plasmid and Strain Generation 
Table 2 lists the oligonucleotides used in this study. The TargeTron system was used to introduce 
a mutation into C. difficile CD2118 through insertion of a mobilizable group II intron into the 
CD2118 coding sequence (10, 14). The CD2118 DNA sequence was entered into the free 
TargeTron web-based algorithm that is maintained by Monash University. This algorithm 
predicts possible insertion sites of the group II intron into the gene. The primers CD2118 (6a) 
IBS, CD2118 (6a) EBS2, CD2118 (6a) EBS1d, and EBS Universal were used to assemble the 
retargeting intron fragment using PCR. The fragment was then ligated into the plasmid pCR2.1-
TOPO (Invitrogen) to yield pSS1. The plasmid pSS1 was transformed into E. coli DH5α. The 
sequence of the insert was confirmed (Eurofins, Operon) and the fragment was liberated from the 
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vector by digesting purified DNA with HinDIII and BsrGI. The fragment was then ligated into 
the vector pJS107, also digested with HinDIII and BsrGI, to produce pSS2. Another method was 
used to determine possible insertion sites, the Targetronics LLC. web-based algorithm, which 
predicts likely insertion sites of the group II intron into the gene based on insertion efficiency 
and then filters the chosen sites based on the probability of insertion at undesired locations in the 
genome. The sequence of the 350-bp fragment that was used to retarget the group II intron to the 
CD2118 gene was compiled by the algorithm and synthesized by Integrated DNA Technologies 
(IDT).  The synthesized DNA fragment was ligated into TOPO Zero Blunt (Invitrogen) and 
transformed into E. coli DH5α, yielding pSS3. The intron fragment in pSS3 was introduced into 
pJS107, as described above for pSS1, yielding pSS4.  The plasmids pSS2 and pSS4 were 
transformed into E. coli MB3436, plasmid DNA extracted and used to transform B. subtilis Bs49 
using standard techniques (12). B. subtilis Bs49 pSS2 and pSS4 were conjugated into C. difficile 
strain UK1. Transconjugants were identified by growth on BHIS medium containing 
thiamphenicol (to select for plasmid-containing C. difficile) and kanamycin (to counter-select B. 
subtilis).  Colonies were then screened for loss of the conjugative transposon Tn916 by 
tetracycline sensitivity (12). Tetracycline-sensitive C. difficile UK1 pSS2 or C. difficile UK1 
pSS4 was plated on BHIS medium supplemented with lincomycin to select for the 
retrotransposition of the group II intron. DNA was then extracted from lincomycin-resistant 
colonies and tested for an intron insertion into CD2118 by amplifying the full-length CD2118 
coding sequence using primers 5’ CD2118 and 3’ CD2118 (15). The 5’ and 3’ junctions of the 
intron insertion site were also amplified using primers CD2118 (6a) IBS and CD2118 (6a) 
EBS1d. 
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TABLE 1. Bacterial strains and plasmids 
Plasmid or strain Key features Reference 
   
Strains   
E. coli   
      DH5α Φ80dlacZΔM15 (Hanahan, 1983) 
      MB3436 recA+ (Wang & Benedik, 2012) 
   
B. subtilis   
      Bs49 CU2189::Tn916 (Haraldsen, 2003) 
   
C. difficile   
      UK1 Clinical isolate (Sorg, 2010)  
   
Plasmids   
pCR2.1-TOPO Amp
R
 and Kan
R
 Invitrogen 
TOPO Zero Blunt  Amp
R
 and Kan
R 
Invitrogen 
pJS107       TargeTron construct derived from pBL100, contains 
Tn916 oriT 
(Sorg, unpublished) 
pSS1 CD2118 intron fragment in pCR2.1-TOPO This Study 
pSS2 CD2118 intron fragment in pJS107 This Study 
pSS3 IDT-synthesized CD2118 intron fragment in TOPO 
Zero Blunt 
This Study 
pSS4 IDT-synthesized CD2118 intron fragment in pJS107 This Study 
 
TABLE 2. Oligonucleotide sequences 
Primer Sequence (5’→ 3’) 
5’ CD2118 AATATTACAGAAGGGAAGAAATGTATG 
3’ CD2118 CTACTCATTAGCTAGCTCCTCCTTTGA 
CD2118 (6a) IBS 
AAAAAAGCTTATAATTATCCTTAGATTTCTTTAAAGTGCGCCCAGAT
AGGGTG 
CD2118 (6a) EBS1d 
CAGATTGTACAAATGTGGTGATAACAGATAAGTCTTTAAATATAACT
TACCTTTCTTTGT 
CD2118 (6a) EBS2 
TGAACGCAAGTTTCTAATTTCGATTAAATCTCGATAGAGGAAAGTGT
CT 
EBS Universal CGAAATTAGAAACTTGCGTTCAGTAAAC 
CD2118 (671a) 
gBlock 
TTCCCCTCTAGAAAAAAGCTTATAATTATCCTTAAGCATCTTAGCAG
TGCGCCCAGATAGGGTGTTAAGTCAAGTAGTTTAAGGTACTACTCTG
TAAGATAACACAGAAAACAGCCAACCTAACCGAAAAGCGAAAGCTG
ATACGGGAACAGAGCACGGTTGGAAAGCGATGAGTTACCTAAAGAC
AATCGGGTACGACTGAGTCGCAATGTTAATCAGATATAAGGTATAA
GTTGTGTTTACTGAACGCAAGTTTCTAATTTCGATTATGCTTCGATAG
AGGAAAGTGTCTGAAACCTCTAGTACAAAGAAAGGTAAGTTAGGTG
CTAAGACTTATCTGTTATCACCACATTTGTACAATCTG 
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CHAPTER III 
RESULTS 
The TargeTron system was used to introduce a mutation into C. difficile CD2118. With this 
method, genes are rendered nonfunctional through site-specific mutation by mobile group II 
intron insertion (14). The sites of insertion into C. difficile CD2118 and intron fragment 
sequences were determined using web-based algorithms. 
 
 
Initially, the web-based algorithm maintained by Monash University was used to generate 
possible TargeTron insertion sites into CD2118.  After the targeting plasmid pSS2 was 
constructed, the DNA was mobilized from B. subtilis to C. difficile UK1. Insertion of the intron 
into the C. difficile chromosome was selected for by incubating C. difficile UK1 pSS2 on agar 
medium supplemented with lincomycin; the plasmid-encoded, retro-transposition-activated 
marker (RAM) provides lincomycin resistance (17). We screened 14 colonies for the insertion of 
the RAM into C. difficile CD2118 by amplifying the full-length CD2118 coding sequence. 
However, upon amplification of CD2118, we did not observe an amplified fragment at the size 
expected for an intron insertion into CD2118 (3.8 kb), suggesting that the intron had inserted 
elsewhere in the C. difficile UK1 genome (Fig. 1). 
 
 
Because we observed aberrant targeting of the intron into the C. difficile genome, we generated a 
different targeting plasmid based upon a different TargeTron algorithm. The Targetronics web-
based algorithm operates in much the same manner as the algorithm maintained by Monash 
University, except that possible insertion sites are also evaluated by the probability of insertion at 
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undesired sites in the genome. A new targeting plasmid (pSS4) was constructed and introduced 
into C. difficile UK1 and the resulting strain screened for lincomycin resistance. Lincomycin-
resistant clones have been observed and purified colonies are currently being isolated. The final 
success of this method has yet to be determined, as research is still ongoing. 
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CHAPTER IV 
CONCLUSIONS 
Because C. difficile germinates in response to bile acids and subsequently survives in the 
presence of these normally toxic molecules, a resistance mechanism may exist (6, 8). In 
preliminary experiments, the effects of cholic acid and deoxycholic acid on gene expression in 
vegetative cells were analyzed using RNAseq. Altered transcript levels were observed for several 
genes, including CD2118 which exhibited a twenty-fold increase in expression compared to the 
negative control condition (Allen and Sorg, unpublished). The results of a BLAST search led to 
its identification as a putative ABC-transporter. In other bacterial species, ABC-transporters have 
been implicated in the resistance to antibiotics and environmental toxins (18). Listeria 
monocytogenes, another Gram-positive intestinal pathogen, utilizes ABC transporters to resist 
the toxic effects of bile (8). This prompted the choice of CD2118 as the gene of interest in this 
project. 
 
 
Two web-based algorithms, one hosted by Monash University and the other by Targetronics, 
LLC., generated the insertion sites into CD2118. This information was used to determine the 
sequence of the targeted intron fragment, which was introduced into C. difficile through 
conjugation. A mutation to CD2118 could not be obtained using the algorithm hosted by Monash 
University, although lincomycin-resistant clones were observed. When these clones were 
analyzed for the presence of the inserted intron DNA, and there were no observable differences 
when compared to CD2118 amplified from wild type C. difficile (Fig. 1). A weakness of this 
algorithm is its inability to evaluate the entire genome for possible aberrant insertions. It is 
entirely possible that the fragment successfully inserted elsewhere in the genome, activating the 
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RAM and conferring lincomycin resistance without affecting CD2118. Because of the lack of 
success using this method, we chose a different algorithm to generate a list of potential insertion 
sites. The second algorithm, hosted by Targetronics, LLC., evaluates both the gene of interest 
and the entire genome, maximizing insertion efficiency while minimizing aberrant insertion. 
Lincomycin-resistant C. difficile growth was observed using this method, but the presence of the 
TargeTron insertion into CD2118 has not yet been verified. A final conclusion about the success 
of this method has not yet been reached, and is dependent on the outcome of forthcoming 
research. 
 
 
In future experiments, the Targetronics, LLC.-based method will be fully assessed for its 
effectiveness in introducing a mutation into CD2118. If CD2118 mutants are obtained, they will 
be tested for altered bile acid resistance by comparing the bile acid MIC to that of wild type. If 
the mutants have diminished resistance, the function of CD2118 will be restored via 
complementation. A complete restoration of the mutant bile acid MIC to wild-type levels will 
confirm that CD2118 plays a major role in C. difficile bile acid resistance.  
 
 
One potential explanation for our observations is that CD2118 is essential for survival of C. 
difficile and that an intron insertion into the CD2118 coding sequence would have detrimental 
effects for the bacterium. Alternatively, the lincomycin-resistant growth observed could be the 
result of chance insertions elsewhere in the genome, as we observed in our first attempt. These 
hypotheses could be tested by using testing several different potential insertion sites in CD2118, 
or a newly developed, allelic-exchange strategy for C. difficile (19).  
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If novel bile acid resistance mechanisms are elucidated for C. difficile, there could be major 
implications for the development of new treatments for CDI. A narrow spectrum antibiotic 
targeting these mechanisms could break the cycle of antibiotic treatment and subsequent CDI 
relapse by preventing the resistance of C. difficile to bile acids; a strategy that would spare the 
gut microbiota. 
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